Clinical Trial Update: Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating hypertonic sodium lactate on a surrogate marker of endothelial leakage in pediatric dengue shock syndrome. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Shock Syndrome

Drugs mentioned

• Hypertonic Sodium Lactate (sodium lactate (hypertonic solution))

Snippet

Sponsor: Innogene Kalbiotech Pte. Ltd | Conditions: Dengue Shock Syndrome | Phase 3 | Status: UNKNOWN